Log in

CVE:VIV - Avivagen Stock Price, Forecast & News

+0.01 (+1.75 %)
(As of 01/23/2020 06:52 AM ET)
Today's Range
Now: C$0.58
50-Day Range
MA: C$0.57
52-Week Range
Now: C$0.58
Volume91,499 shs
Average Volume38,256 shs
Market CapitalizationC$21.70 million
P/E RatioN/A
Dividend YieldN/A
Avivagen Inc. develops and commercializes various products to replace antibiotics in livestock feeds to optimize the health and growth of the animals by supporting the animal's own health defenses. The company offers products based on its OxC-Beta technology, such as OxC-beta Livestock, a premix for livestock feeds; and Vivamune Health Chews supplements for companion animals. The company was formerly known as Chemaphor, Inc. and changed its name to Avivagen Inc.in May 2012. The company is headquartered in Ottawa, Canada.

Industry, Sector and Symbol

Industry Drug Manufacturers - Major



Sales & Book Value

Annual SalesC$977,451.00
Cash FlowC$0.03 per share
Book ValueC($0.09) per share



Market CapC$21.70 million
Next Earnings Date1/30/2020 (Estimated)

Receive VIV News and Ratings via Email

Sign-up to receive the latest news and ratings for VIV and its competitors with MarketBeat's FREE daily newsletter.

Avivagen (CVE:VIV) Frequently Asked Questions

What is Avivagen's stock symbol?

Avivagen trades on the Canadian Venture Exchange (CVE) under the ticker symbol "VIV."

When is Avivagen's next earnings date?

Avivagen is scheduled to release their next quarterly earnings announcement on Thursday, January 30th 2020. View Earnings Estimates for Avivagen.

Has Avivagen been receiving favorable news coverage?

News coverage about VIV stock has trended somewhat negative this week, according to InfoTrie. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Avivagen earned a news impact score of -1.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Avivagen.

Who are some of Avivagen's key competitors?

What other stocks do shareholders of Avivagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avivagen investors own include ProMetic Life Sciences (PLI) and Snc-Lavalin Group (SNCAF).

Who are Avivagen's key executives?

Avivagen's management team includes the folowing people:
  • Mr. G. F. Kym Anthony, Chairman, Interim CEO & Pres (Age 63)
  • Dr. Graham Burton, Co-Founder, Chief Scientific Officer & Director
  • Mr. Christopher Boland, Chief Financial Officer
  • Dr. Janusz Daroszewski, Co-Founder and Director of Product Devel. & Quality Assurance
  • Mr. Drew Basek, Director of Investor Relations

How do I buy shares of Avivagen?

Shares of VIV and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Avivagen's stock price today?

One share of VIV stock can currently be purchased for approximately C$0.58.

How big of a company is Avivagen?

Avivagen has a market capitalization of C$21.70 million and generates C$977,451.00 in revenue each year. Avivagen employs 13 workers across the globe.View Additional Information About Avivagen.

What is Avivagen's official website?

The official website for Avivagen is http://www.avivagen.com/.

How can I contact Avivagen?

The company can be reached via phone at 613-949-8164.

MarketBeat Community Rating for Avivagen (CVE VIV)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  15 (Vote Outperform)
Underperform Votes:  15 (Vote Underperform)
Total Votes:  30
MarketBeat's community ratings are surveys of what our community members think about Avivagen and other stocks. Vote "Outperform" if you believe VIV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VIV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel